Petrelintide: A New Amylin-Based Drug for Obesity and Diabetes
Obesity and type 2 diabetes remain significant global health challenges, with pharmaceutical companies continuously exploring innovative treatments. One such advancement is petrelintide, an experimental drug developed by Roche and Zealand Pharma. This once-weekly injectable medication mimics amylin, a hormone produced by the pancreas that helps regulate appetite and food intake. Early trials suggest it could offer a viable alternative to GLP-1 drugs like Wegovy and Zepbound, which are associated with gastrointestinal side effects in many patients.
How Petrelintide Works
Petrelintide belongs to a class of drugs targeting the amylin hormone, which signals the brain to reduce food consumption and delays gastric emptying. Unlike GLP-1 drugs, which act on the gut, amylin works through the pancreas. This distinction may explain why petrelintide has shown fewer gastrointestinal issues in clinical trials.
According to Dr. Wayne Ho, a clinical investigator in diabetes and obesity, “Amylin slows gastric emptying, enhancing the feeling of fullness. This mechanism may reduce the risk of nausea and vomiting compared to GLP-1 medications.”
Phase 2 Trial Results
A phase 2 trial involving nearly 500 participants with obesity or overweight (average BMI 37) demonstrated promising results. Participants taking petrelintide achieved up to 10.7% weight loss over 42 weeks, compared to 1.7% in the placebo group. Notably, there were no cases of vomiting and no participants discontinued treatment due to gastrointestinal side effects.
Dr. W. Timothy Garvey, lead study author, emphasized the significance of these findings: “This is safe, moderate weight loss that most patients with obesity require. Why should treatment cause sickness? We need better options.”
Comparing Amylin and GLP-1 Drugs
While GLP-1 drugs like tirzepatide have shown greater weight loss (up to 20% or more), petrelintide’s benefits lie in its better tolerability. Many patients discontinue GLP-1 therapies due to nausea and vomiting. However, amylin-based drugs may not always match the weight loss efficacy of GLP-1s. For instance, trials of the amylin drug eloralintide showed 20% weight loss at high doses, while combinations of amylin and GLP-1 drugs (e.g., cagrilintide with semaglutide) have achieved up to 22.7% weight loss.
Dr. Garvey noted, “Not all patients need 25-30% weight loss. Safety and tolerability are critical factors.”
Future Prospects and Other Amylin-Based Drugs
Petrelintide is part of a broader trend in obesity research. Other companies, including Eli Lilly, Novo Nordisk, and AbbVie, are also developing amylin-targeting therapies. Currently, pramlintide (Symlin) is the only FDA-approved amylin-based medication, though it is primarily used as an add-on for diabetes patients.
Dr. Ho added, “This is an exciting time for obesity research. Amylin drugs could become a first-line treatment, depending on further trials.”
Key Takeaways
- Petrelintide is an amylin-based drug showing up to 10.7% weight loss in phase 2 trials.
- It has fewer gastrointestinal side effects compared to GLP-1 medications like Wegovy.
- While not as effective as some GLP-1s in weight loss, its tolerability may make it a preferred option for some patients.
- Other amylin-based drugs, such as eloralintide and cagrilintide, are in development.
FAQ
What is petrelintide?
Petrelintide is an experimental drug under development by Roche and Zealand Pharma. It mimics the hormone amylin, which helps regulate appetite and food intake.
How does it differ from GLP-1 drugs?
GLP-1 drugs target the gut, while petrelintide targets the pancreas. This difference may lead to fewer gastrointestinal side effects.
What were the trial results?
In a phase 2 trial, petrelintide led to up to 10.7% weight loss over 42 weeks, with no cases of vomiting or treatment discontinuation due to side effects.